A patient support program has been established to transition patients to Egrifta WR, which will gradually replace Egrifta SV. Egrifta WR™, a new concentrated formulation (F8) of tesamorelin, is now ...
(RTTNews) - Theratechnologies Inc. (THTX, TH.TO) announced the availability of EGRIFTA WR (tesamorelin) for injection, approved earlier this year by the U.S. Food and Drug Administration, for the ...
According to Theratechnologies, Egrifta WR is set to replace Egrifta SV. The Food and Drug Administration (FDA) has approved Egrifta WR ™, a new concentrated formulation (F8) of tesamorelin, for the ...
MONTREAL, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage ...
Tesamorelin for injection is approved in the U.S. for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy*. Tesamorelin for injection is a growth hormone- releasing ...
Tesamorelin 2mg; per vial; lyophilized pwd for SC inj after reconstitution; preservative-free; contains mannitol. Store at room temperature at 20°C to 25°C (68°F to 77°F) in the original box to ...
MONTREAL, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the ...
MONTREAL, April 08, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results